Recovery of Erectile Function After Nerve Sparing Radical Prostatectomy and Penile Rehabilitation With Nightly Intraurethral Alprostadil Versus Sildenafil Citrate
Open Access
- 30 June 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 183 (6), 2451-2456
- https://doi.org/10.1016/j.juro.2010.01.062
Abstract
To our knowledge we report the first large, randomized, prospective penile rehabilitation clinical trial to compare the effectiveness of nightly intraurethral alprostadil vs sildenafil citrate after nerve sparing prostatectomy. We performed a prospective, randomized, open label, multicenter American study in men with normal erectile function who underwent bilateral nerve sparing radical prostatectomy. The International Index of Erectile Function erectile function domain was the primary end point. Subjects initiated nightly treatment within 1 month of surgery with intraurethral alprostadil or oral sildenafil citrate (50 mg) for 9 months. After 1-month washout and before sexual activity subjects self-administered sildenafil citrate (100 mg) for a total of 6 attempts in 1 month. Secondary end points were the global assessment question, sexual encounter profile, Erectile Dysfunction Inventory of Treatment Satisfaction and measured stretched penile length. Of 139 men who started intraurethral alprostadil and 73 who started sildenafil citrate, 97 and 59, respectively, completed the trial. There were no statistically significant differences in International Index of Erectile Function erectile function domain and intercourse success rates to intraurethral alprostadil. The global assessment question was significantly better only at 6 months for intraurethral alprostadil (p <0.028). At completion there were no differences between treatments for any of the end points. This is the first study to directly compare the ability of alprostadil and a phosphodiesterase-5 inhibitor to enhance penile recovery subsequent to bilateral nerve sparing radical prostatectomy. The use of nightly subtherapeutic intraurethral alprostadil is well tolerated after radical prostatectomy. The benefit to return of erectile function of nightly sildenafil citrate and subtherapeutic intraurethral alprostadil appears to be comparable within the first year of surgery.Keywords
This publication has 10 references indexed in Scilit:
- THE LONGITUDINAL EFFECTS ON PENILE OXYGEN SATURATION FROM A PROSPECTIVE RANDOMIZED STUDY OF THE NIGHTLY USE OF INTRAURETHRAL ALPROSTADIL VS SILDENAFIL FOLLOWING NERVE SPARING RADICAL PROSTATECTOMY (NSRP)Journal of Urology, 2009
- ACUTE CHANGES IN PENILE OXIMETRY AFTER SINGLE UTILIZATION OF THE VACUUM ERECTION DEVICE (VED) COMPARED TO INTRAURETHRAL ALPROSTATDIL (IUA) AND INTRCAVERNOSAL INJECTIONS (ICI) IN PATIENTS FOLLOWING RADICAL PROSTATECTOMY (RP)Journal of Urology, 2009
- Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical ProstatectomyEuropean Urology, 2008
- Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomyInternational Journal of Impotence Research, 2008
- 5-Year Urinary and Sexual Outcomes After Radical Prostatectomy: Results From the Prostate Cancer Outcomes StudyJournal of Urology, 2008
- Quality of Life and Satisfaction with Outcome among Prostate-Cancer SurvivorsThe New England Journal of Medicine, 2008
- Recovery of erectile function after nerve‐sparing radical prostatectomy: improvement with nightly low‐dose sildenafilBJU International, 2008
- The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activityBJU International, 2007
- Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska NativesCancer, 2007
- Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate CancerJAMA, 2000